Sales for the third quarter had a 35% drop year-over-year due to a variety of factors, ranging from the population already being vaccinated to unique production challenges. The supply chain issues originated from different vaccine requests from Europe and the U.S. since the latter decided to pursue a BA.4/BA.5 bivalent booster rather than an Omicron /BA.1 booster. This put the capability of Moderna and the mRNA platform in a compromising situation.